Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma

Abstract

Glioblastoma-targeted drug delivery systems facilitate efficient delivery of chemotherapeutic agents to malignant gliomas, while minimizing systemic toxicity and side effects. Taking advantage of the fibrin deposition that is characteristic of tumors, we constructed spherical, Cy7-labeled, targeting micelles to glioblastoma through the addition of the fibrin-binding pentapeptide, cysteine-arginine-glutamic acid-lysine-alanine, or CREKA. Conjugation of the CREKA peptide to Cy7-micelles increased the average particle size and zeta potential. Upon intravenous administration to GL261 glioma bearing mice, Cy7-micelles passively accumulated at the brain tumor site via the enhanced permeability and retention (EPR) effect, and Cy7-CREKA-micelles displayed enhanced tumor homing via active targeting as early as 1 h after administration, as confirmed via in vivo and ex vivo imaging and immunohistochemistry. Biodistribution of micelles showed an accumulation within the liver and kidneys, leading to micelle elimination via renal clearance and the reticuloendothelial system (RES). Histological evaluation showed no signs of cytotoxicity or tissue damage, confirming the safety and utility of this nanoparticle system for delivery to glioblastoma. Our findings offer strong evidence for the glioblastoma-targeting potential of CREKA-micelles and provide the foundation for CREKA-mediated, targeted therapy of glioma.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 35

1. 1.

   Preusser M, de Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M, et al. Current concepts and management of glioblastoma. Ann Neurol. 2011;70:9-21.

   Not in our library10.1002/ana.22425

2. 2.

   Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-66.

   Not in our library10.1016/s1470-2045(09)70025-7

3. 3.

   Ong BYS, Ranganath SH, Lee LY, Lu F, Lee H-S, Sahinidis NV, et al. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials. 2009;30:3189-96.

   Not in our library10.1016/j.biomaterials.2009.02.030

4. 4.

   Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, et al. A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. Cancer. 2001;91:417-22.

   Not in our library10.1002/1097-0142(20010115)91:2<417::aid-cncr1016>3.0.co;2-9

5. 5.

   Zhou J, Atsina KB, Himes BT, Strohbehn GW, Saltzman WM. Novel delivery strategies for glioblastoma. Cancer J. 2012;18:89-99.

   Not in our library10.1097/ppo.0b013e318244d8ae

6. 6.

   Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24:1733-44.

   Not in our library10.1007/s11095-007-9324-2

7. 7.

   Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials. 2012;33:8167-76.

   Not in our library10.1016/j.biomaterials.2012.07.046

8. 8.

   Gu G, Xia H, Hu Q, Liu Z, Jiang M, Kang T, et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials. 2013;34:196-208.

   Not in our library10.1016/j.biomaterials.2012.09.044

9. 9.

   Kuo Y-C, Liang C-T. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials. 2011;32:3340-50.

   Not in our library10.1016/j.biomaterials.2011.01.048

10. 10.

    Zhang P, Hu L, Yin Q, Zhang Z, Feng L, Li Y. Transferrin-conjugated poly-phosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release. 2012;159:429-34.

    Not in our library10.1016/j.jconrel.2012.01.031

11. 11.

    Peer D, Karp JM, Hong S, FaroKhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-60.

    Not in our library10.1038/nnano.2007.387

12. 12.

    Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24:1-16.

    Not in our library10.1007/s11095-006-9132-0

13. 13.

    Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine. 2010;6:714-29.

    Not in our library10.1016/j.nano.2010.05.005

14. 14.

    Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Progress Polym Sci. 2007;32:1054-82.

    Not in our library10.1016/j.progpolymsci.2007.05.014

15. 15.

    Gilmore JL, Yi X, Quan L, Kabanov AV. Novel nanomaterials for clinical neuroscience. J Neuroimmune Pharmacol. 2008;3:83-94.

    Not in our library10.1007/s11481-007-9099-6

16. 16.

    Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol. 2003;162:1747-57.

    Not in our library10.1016/s0002-9440(10)64309-x

17. 17.

    Dvorak H, Senger D, Dvorak A, Harvey V, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science. 1985;227:1059-61.

    Not in our library10.1126/science.3975602

18. 18.

    Agemy L, Sugahara KN, Kotamraju VR, Gujraty K, Girard OM, Kono Y, et al. Nanoparticle-induced vascular blockade in human prostate cancer. Blood. 2010;116:2847-56.

    Not in our library10.1182/blood-2010-03-274258

19. 19.

    Bardos H, Molnar P, Csecsei G, Adany R. Fibrin deposition in primary and metastatic human brain tumours. Blood Coagul Fibrinolysis. 1996;7:536-48.

    Not in our library

20. 20.

    Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A. 2007;104:932-6.

    Not in our library10.1073/pnas.0610298104

21. 21.

    Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, et al. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A. 2009;106:9815-9.

    Not in our library10.1073/pnas.0903369106

22. 22.

    Chattopadhyay A, London E. Fluorimetric determination of critical micelle concentration avoiding interference from detergent charge. Anal Biochem. 1984;139:408-12.

    Not in our library10.1016/0003-2697(84)90026-5

23. 23.

    Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release. 2007;124:163-71.

    Not in our library10.1016/j.jconrel.2007.09.007

24. 24.

    Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008-12.

    Not in our library10.1016/s0140-6736(95)90755-6

25. 25.

    Kastantin M, Ananthanarayanan B, Karmali P, Ruoslahti E, Tirrell M. Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir. 2009;25:7279-86.

    Not in our library10.1021/la900310k

26. 26.

    Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505-15.

    Not in our library10.1021/mp800051m

27. 27.

    Gu G, Gao X, Hu Q, Kang T, Liu Z, Jiang M, et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials. 2013;34:5138-48.

    Not in our library10.1016/j.biomaterials.2013.03.036

28. 28.

    Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, et al. Lactoferrin-conjugated PEG–PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2009;134:55-61.

    Not in our library10.1016/j.jconrel.2008.10.016

29. 29.

    Kobayashi H, Ogawa M, Alford R, Choyke PL, Urano Y. New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev. 2009;110:2620-40.

    Not in our library10.1021/cr900263j

30. 30.

    Duan X, Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small. 2013;9:1521-32.

    Not in our library10.1002/smll.201201390

31. 31.

    Arnida, Janát-Amsbury MM, Ray A, Peterson CM, Ghandehari H. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm. 2011;77:417-23.

    Not in our library10.1016/j.ejpb.2010.11.010

32. 32.

    Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces. 2008;66:274-80.

    Not in our library10.1016/j.colsurfb.2008.07.004

33. 33.

    Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5:487-95.

    Not in our library10.1021/mp800032f

34. 34.

    Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine. 2008;3:703-17.

    Not in our library10.2217/17435889.3.5.703

35. 35.

    Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165-70.

    Not in our library10.1038/nbt1340

Cited by papers we hold 2

• A Historical Review of Brain Drug Delivery · 2022
  No notice
• Multifunctional polymeric micelles for delivery of drugs and siRNA · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.